Infliximab Preferentially Induces Clinical Remission and Mucosal Healing in Short Course Crohn’s Disease with Luminal Lesions through Balancing Abnormal Immune Response in Gut Mucosa
Table 1
Characteristics of patients with CD in our study.
Gender (M/F)
77/29
Mean duration of disease before IFX in months
38.7 ± 42.9
Mean age of diagnosis in yrs
27.2 ± 9.7
A1 (≤16 yrs)
10 (9.4%)
A2 (17–40 yrs)
85 (80.2%)
A3 (>40 yrs)
11 (10.4%)
Location
L1 (ileum only)
18 (17.0%)
L2 (colon only)
22 (20.8%)
L3 (ileocolonic)
66 (62.3%)
L4*
0
Behavior
B1 (nonstricturing, nonpenetrating)
49 (46.2%)
B2 (stricturing)
29 (27.4%)
B3 (penetrating)
28 (26.4%)
32 (30.2%)
Fistula
Perianal
28 (26.4%)
Enterocutaneous
3 (4.8%)
Enterovaginal
3 (2.8%)
Intestinal
12 (11.3%)
Current smoker
19 (17.9%)
Previous CD-related abdominal surgery
12 (11.3%)
Step-up/top-down strategy
57/49
A modifier that can be added to L1–L3 when concomitant upper gastrointestinal disease is present. Added to B1–B3 when concomitant perianal disease is present.
